Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2025 08:05 ET | Source: SeaStar Medical

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients...
March 27, 2025 16:05 ET | Source: SeaStar Medical

SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

DENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients...
October 15, 2024 08:30 ET | Source: SeaStar Medical Holding Corporation

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

DENVER, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
August 29, 2023 08:00 ET | Source: SeaStar Medical Holding Corporation

Case Series of Three Critically Ill Children with Acute Kidney Injury Safely Treated with SeaStar Medical’s Selective Cytopheretic Device Published in the Journal Blood Purification

DENVER, Aug. 29, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
June 20, 2023 16:05 ET | Source: SeaStar Medical Holding Corporation

First Patient Enrolled in SeaStar Medical’s Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

DENVER, June 20, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
April 19, 2023 08:00 ET | Source: SeaStar Medical Holding Corporation

SeaStar Medical Announces Activation of First Clinical Site in Pivotal Trial with Selective Cytopheretic Device in Critically Ill Adults with Acute Kidney Injury

DENVER, April 19, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of...
February 09, 2023 08:19 ET | Source: SeaStar Medical Holding Corporation

SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

Patient enrollment in pivotal clinical study expected to begin in March DENVER, Feb. 09, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical device company developing proprietary...
January 05, 2023 10:15 ET | Source: Potrero Medical

Potrero Medical to Present at 41th Annual J.P. Morgan Healthcare Conference

HAYWARD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Potrero Medical, innovator of the Accuryn Monitoring System, announced today that it accepted an invitation to present at the 41st Annual J.P....
November 03, 2022 09:00 ET | Source: SeaStar Medical Holding Corporation

SeaStar Medical (Nasdaq: ICU) Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children

Data being presented at the American Society of Nephrology (ASN) Kidney Week 2022 Interim study data show that SCD treatment is safe to use in pediatric patients with Acute Kidney Injury (AKI)...
October 16, 2020 07:00 ET | Source: Arch Biopartners

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial...